Metallothionein, copper and alpha-synuclein in alpha-synucleinopathies

Frontiers in Neuroscience

Volumn 11, Issue APR, 2017, Pages

  Okita, Yuho ^a   Rcom H'cheo Gauthier, Alexandre N ^a   Goulding, Michael ^a   Chung, Roger S ^b   Faller, Peter ^c   Pountney, Dean L ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b MACQUARIE UNIVERSITY   (Australia)

^c UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

A synuclein; Copper; Dementia with lewy bodies; Metallothionein; Multiple system atrophy; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; COPPER; DEXAMETHASONE; MENKES PROTEIN; METALLOTHIONEIN; METALLOTHIONEIN I; METALLOTHIONEIN II; METALLOTHIONEIN III; NEUROMELANIN; REACTIVE OXYGEN METABOLITE;

ALPHA SYNUCLEINOPATHY; ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYOTROPHIC LATERAL SCLEROSIS; COPPER BLOOD LEVEL; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; HUMAN; LEUKODYSTROPHY; LYSOSOME STORAGE DISEASE; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN DEGRADATION; SHORT SURVEY; SHY DRAGER SYNDROME; SUBSTANTIA NIGRA;

EID: 85018403205     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2017.00114     Document Type: Short Survey

References (139)

1. Adam, P., Krížková, S., Heger, Z., Babula, P., Pekarík, V., Vaculovicoá, M., et al. (2016). Metallothioneins in prion-and amyloid-related diseases. J. Alzheimers. Dis. 51, 637-656. doi: 10.3233/JAD-150984
2. Adlard, P. A., Cherny, R. A., Finkelstein, D. I., Gautier, E., Robb, E., Cortes, M., et al. (2008). Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aß. Neuron 59, 43-55. doi: 10.1016/j.neuron.2008.06.018
3. Anandhan, A., Rodriguez-Rocha, H., Bohovych, I., Griggs, A. M., Zavala-Flores, L., Reyes-Reyes, E. M., et al. (2015). Overexpression of alpha-synuclein at non-toxic levels increases dopaminergic cell death induced by copper exposure via modulation of protein degradation pathways. Neurobiol. Dis. 81, 76-93. doi: 10.1016/j.nbd.2014.11.018
4. Arnal, N., Cristalli, D. O., de Alaniz, M. J., and Marra, C. A. (2010). Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res. 1319, 118-130. doi: 10.1016/j.brainres.2009.11.085
5. Bachhuber, T., Katzmarski, N., McCarter, J. F., Loreth, D., Tahirovic, S., Kamp, F., et al. (2015). Inhibition of amyloid-[beta] plaque formation by [alpha]-synuclein. Nat. Med. 21, 802-807. doi: 10.1038/nm.3885
6. Barnham, K. J., and Bush, A. I. (2008). Metals in alzheimer's and parkinsons diseases. Curr. Opin. Chem. Biol. 12, 222-228. doi: 10.1016/j.cbpa.2008.02.019
7. Barnham, K. J., Masters, C. L., and Bush, A. I. (2004). Neurodegenerative diseases and oxidative stress-a report. Nat. Rev. Drug Discov. 3, 205-210. doi: 10.1038/nrd1330
8. Beach, T. G., Adler, C. H., Dugger, B. N., Serrano, G., Hidalgo, J., Henry-Watson, J., et al. (2013). Submandibular gland biopsy for the diagnosis of Parkinson disease. J. Neuropathol. Exp. Neurol. 72, 130-136. doi: 10.1097/NEN.0b013e3182805c72
9. Blesa, J., Trigo-Damas, I., Quiroga-Varela, A., and Jackson-Lewis, V. R. (2015). Oxidative stress and Parkinson's disease. Front Neuroanat. 9:91. doi: 10.3389/fnana.2015.00091
10. Branco, D. M., Arduino, D. M., Esteves, A. R., Silva, D. F., Cardoso, S. M., and Oliveira, C. (2010). Cross-talk between mitochondria and proteasome in Parkinson's disease pathogenesis. Front. Aging Neurosci. 2:17. doi: 10.3389/fnagi.2010.00017
11. Brewer, G. J. (2009). Risks of copper and iron toxicity during aging in humans. Chem. Res. Toxicol. 23, 319-326. doi: 10.1021/tx900338d
12. Camponeschi, F., Valensin, D., Tessari, I., Bubacco, L., Dell'Acqua, S., Casella, L., et al. (2013). Copper (I)-a-synuclein interaction: structural description of two independent and competing metal binding sites. Inorg. Chem. 52, 1358-1367. doi: 10.1021/ic302050m
13. Carboni, E., and Lingor, P. (2015). Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease. Metallomics 7, 395-404. doi: 10.1039/c4mt00339j
14. Carpenè, E., Andreani, G., and Isani, G. (2007). Metallothionein functions and structural characteristics. J. Trace Elem. Med. Biol. 21, 35-39. doi: 10.1016/j.jtemb.2007.09.011
15. Carter, A. D., Felber, B. K., Walling, M., Jubier, M. F., Schmidt, C. J., and Hamer, D. H. (1984). Duplicated heavy metal control sequences of the mouse metallothionein-I gene. Proc. Natl. Acad. Sci. U.S.A. 81, 7392-7396. doi: 10.1073/pnas.81.23.7392
16. Cesani, M., Cavalca, E., Macco, R., Leoncini, G., Terreni, M. R., Lorioli, L., et al. (2014). Metallothioneins as dynamic markers for brain disease in lysosomal disorders. Ann. Neurol. 75, 127-137. doi: 10.1002/ana.24053
17. Chai, C., and Lim, K.-L. (2013). Genetic insights into sporadic Parkinson's disease pathogenesis. Curr. Genomics 14, 486-501. doi: 10.2174/1389202914666131210195808
18. Chen, L. I., and Feany, M. B. (2005). a-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8, 657-663. doi: 10.1038/nn1443
19. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., et al. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits ß-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676. doi: 10.1016/s0896-6273(01)00317-8
20. Choi, B.-S., and Zheng, W. (2009). Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res. 1248, 14-21. doi: 10.1016/j.brainres.2008.10.056
21. Chung, R. S., Howells, C., Eaton, E. D., Shabala, L., Zovo, K., Palumaa, P., et al. (2010). The native copper-and zinc-binding protein metallothionein blocks copper-mediated Aß aggregation and toxicity in rat cortical neurons. PLoS ONE 5:e12030. doi: 10.1371/journal.pone.0012030
22. Chung, R. S., Leung, Y. K., Butler, C. W., Chen, Y., Eaton, E. D., Pankhurst, M. W., et al. (2009). Metallothionein treatment attenuates microglial activation and expression of neurotoxic quinolinic acid following traumatic brain injury. Neurotox. Res. 15, 381-389. doi: 10.1007/s12640-009-9044-y
23. Chung, R. S., Penkowa, M., Dittmann, J., King, C. E., Bartlett, C., Asmussen, J. W., et al. (2008). Redefining the role of metallothionein within the injured brain Extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J. Biol. Chem. 283, 15349-15358. doi: 10.1074/jbc.M708446200
24. Chung, R. S., Vickers, J. C., Chuah, M. I., and West, A. K. (2003). Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J. Neurosci. 23, 3336-3342
25. Connolly, B. S., and Lang, A. E. (2014). Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670-1683. doi: 10.1001/jama.2014.3654
26. Cremades, N., Cohen, S. I. A., Deas, E., Abramov, A. Y., Chen, A. Y., Orte, A., et al. (2012). Direct observation of the interconversion of normal and toxic forms of a-synuclein. Cell 149, 1048-1059. doi: 10.1016/j.cell.2012.03.037
27. Dauer, W., and Prezedborski, S. (2003). Parkinson's disease: mechanism and models. Neuron 39, 889-909. doi: 10.1016/S0896-6273(03)00568-3
28. Davies, K. M., Bohic, S., Carmona, A., Ortega, R., Cottam, V., Hare, D. J., et al. (2014). Copper pathology in vulnerable brain regions in Parkinson's disease. Neurobiol. Aging 35, 858-866. doi: 10.1016/j.neurobiolaging.2013.09.034
29. Davies, K. M., Hare, D. J., Cottam, V., Chen, N., Hilgers, L., Halliday, G., et al. (2013). Localization of copper and copper transporters in the human brain. Metallomics 5, 43-51. doi: 10.1039/C2MT20151H
30. Davies, K. M., Mercer, J. F., Chen, N., and Double, K. L. (2016). Copper dyshomoeostasis in Parkinson's disease: implications for pathogenesis and indications for novel therapeutics. Clin. Sci. 130, 565-574. doi: 10.1042/CS20150153
31. De Ricco, R., Valensin, D., Dell'Acqua, S., Casella, L., Dorlet, P., Faller, P., et al. (2015a). Remote His50 acts as a coordination switch in the high-affinity N-terminal centered copper (II) site of a-synuclein. Inorg. Chem. 54, 4744-4751. doi: 10.1021/acs.inorgchem.5b00120
32. De Ricco, R., Valensin, D., Dell'Acqua, S., Casella, L., Hureau, C., and Faller, P. (2015b). Copper (I/II), a/ß-Synuclein and Amyloid-ß: menage à Trois? ChemBioChem 16, 2319-2328. doi: 10.1002/cbic.201500425
33. Dong, G., Chen, H., Qi, M., Dou, Y., and Wang, Q. (2015). Balance between metallothionein and metal response element binding transcription factor 1 is mediated by zinc ions (Review). Mol. Med. Rep. 11, 1582-1586. doi: 10.3892/mmr.2014.2969
34. Drew, S. C., Ling Leong, S., Pham, C. L., Tew, D. J., Masters, C. L., Miles, L. A., et al. (2008). Cu2+ binding modes of recombinant a-synuclein-insights from EPR spectroscopy. J. Am. Chem. Soc. 130, 7766-7773. doi: 10.1021/ja800708x
35. Dryanovski, D. I., Guzman, J. N., Xie, Z., Galteri, D. J., Volpicelli-Daley, L. A., Lee, V. M. Y., et al. (2013). Calcium entry and a-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 33, 10154-10164. doi: 10.1523/jneurosci.5311-12.2013
36. Ebadi, M., and Sharma, S. (2006). Metallothioneins 1 and 2 attenuate peroxynitrite-induced oxidative stress in Parkinson disease. Exp. Biol. Med. 231, 1576-1583. doi: 10.1177/153537020623100919
37. Ebadi, M., Brown-Borg, H., El Refaey, H., Singh, B. B., Garrett, S., Shavali, S., et al. (2005). Metallothionein-mediated neuroprotection in genetically engineered mouse models of Parkinson's disease. Brain Res. Mol. Brain Res. 134, 67-75. doi: 10.1016/j.molbrainres.2004.09.011
38. Espay, A. J., Schwarzschild, M. A., Tanner, C. M., Fernandez, H. H., Simon, D. K., Leverenz, J. B., et al. (2017). Biomarker-driven phenotyping in Parkinson's disease: a translational missing link in disease-modifying clinical trials. Mov. Disord. 32, 319-324. doi: 10.1002/mds.26913
39. Faller, P. (2010). Neuronal growth inhibitory factor (metallothionein-3): reactivity and structure of metal-thiolate clusters. FEBS J. 277, 2921-2930. doi: 10.1111/j.1742-4658.2010.07717.x
40. Finkelstein, D. I., Hare, D. J., Billings, J. L., Sedjahtera, A., Nurjono, M., Arthofer, E., et al. (2016). Clioquinol improves cognitive, motor function, and microanatomy of the Alpha-synuclein hA53T transgenic mice. ACS Chem. Neurosci. 7, 119-129. doi: 10.1021/acschemneuro.5b00253
41. Fitzgerald, M., Nairn, P., Bartlett, C. A., Chung, R. S., West, A. K., and Beazley, L. D. (2007). Metallothionein-IIA promotes neurite growth via the megalin receptor. Exp. Brain Res. 183, 171-180. doi: 10.1007/s00221-007-1032-y
42. Follett, J., Norwood, S. J., Hamilton, N. A., Mohan, M., Kovtun, O., Tay, S., et al. (2014). The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. Traffic 15, 230-244. doi: 10.1111/tra.12136
43. Halliwell, B. (2001). Role of free radicals in the neurodegenerative diseases. Drugs Aging 18, 685-716. doi: 10.2165/00002512-200118090-00004
44. Hart, R. G., Pearce, L. A., Ravina, B. M., Yaltho, T. C., and Marler, J. R. (2009). Neuroprotection trials in Parkinson's disease: systematic review. Mov. Disord. 24, 647-654. doi: 10.1002/mds.22432
45. Howells, C., West, A. K., and Chung, R. S. (2010). Neuronal growth-inhibitory factor (metallothionein-3): evaluation of the biological function of growth-inhibitory factor in the injured and neurodegenerative brain. FEBS J. 277, 2931-2939. doi: 10.1111/j.1742-4658.2010.07718.x
46. Hozumi, I. (2013). Roles and therapeutic potential of metallothioneins in neurodegenerative diseases. Curr. Pharm. Biotechnol. 14, 408-413. doi: 10.2174/1389201011314040004
47. Hozumi, I., Asanuma, M., Yamada, M., and Uchida, Y. (2004). Metallothioneins and neurodegenerative diseases. J. Health Sci. 50, 323-331. doi: 10.1248/jhs.50.323
48. Hozumi, I., Hasegawa, T., Honda, A., Ozawa, K., Hayashi, Y., Hashimoto, K., et al. (2011). Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J. Neurol. Sci. 303, 95-99. doi: 10.1016/j.jns.2011.01.003
49. Jankovic, J. J. (2012). Current concepts in parkinson's disease and other movement disorders. Curr. Opin. Neurol. 25, 429-432. doi: 10.1097/WCO.0b013e3283550cdd
50. Jellinger, K. A. (2014). Neuropathology of multiple system atrophy: new thoughts about pathogenesis. Mov. Disord. 29, 1720-1741. doi: 10.1002/mds.26052
51. Jenner, P., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben-Shlomo, Y., et al. (2013). Parkinson's disease-the debate on the clinical phenomenology, aetiology, pathology and pathogenesis. J. Parkinson's Dis. 3, 1-11. doi: 10.3233/JPD-130175
52. Jucker, M., and Walker, L. C. (2013). Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51. doi: 10.1038/nature12481
53. Kägi, J. H., and Vallee, B. L. (1960). Metallothionein: a cadmium-and zinc-containing protein from equine renal cortex. J. Biol. Chem. 235, 3460-3465
54. Karin, M., Haslinger, A., Holtgreve, H., Richards, R. I., Krauter, P., Westphal, H. M., et al. (1984). Characterization of DNA sequences through which cadmium and glucocorticoid hormones induce human metallothionein-IIA gene. Nature 308, 513-519. doi: 10.1038/308513a0
55. Karin, M., Herschman, H. R., and Weinstein, D. (1980). Primary induction of metallothionein by dexamethasone in cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 92, 1052-1059. doi: 10.1016/0006-291X(80)90808-6
56. Kelly, E. J., and Palmiter, R. D. (1996). A murine model of Menkes disease reveals a physiological function of metallothionein. Nat. Genet. 13, 219-222. doi: 10.1038/ng0696-219
57. Kimura, T., and Itoh, N. (2008). Function of metallothionein in gene expression and signal transduction: newly found protective role of metallothionein. J. Health Sci. 54, 251-260. doi: 10.1248/jhs.54.251
58. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., et al. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of a-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780-2791
59. Kitada, T., Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608. doi: 10.1038/33416
60. Klaassen, C. D. (1981). Induction of metallothionein by adrenocortical steroids. Toxicology 20, 275-279. doi: 10.1016/0300-483X(81)90034-2
61. Kobayashi, S., Okada, T., and Kimura, M. (1985). Effects of dexamethasone on metallothionein induction by Zn, Cu and Cd in chang liver cells. Chem. Biol. Interact. 55, 347-356. doi: 10.1016/S0009-2797(85)80141-1
62. Krizkova, S., Masarik, M., Majzlik, P., Kukacka, J., Kruseova, J., Adam, V., et al. (2010). Serum metallothionein in newly diagnosed patients with childhood solid tumours. Acta Biochim. Pol. 57, 561
63. Kukacka, J., Vajtr, D., Huska, D., Prusa, R., Houstava, L., Samal, F., et al. (2006). Blood metallothionein, neuron specific enolase, and protein S100B in patients with traumatic brain injury. Neuroendocrinol. Lett. 27, 116-120
64. Kurasaki, M., Okabe, M., Saito, S., and Suzuki-Kurasaki, M. (1998). Copper metabolism in the kidney of rats administered copper and copper-metallothionein. Am. J. Physiol. 274, F783-F790
65. Kurkowska-Jastrzebska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybylkowski, A., Czlonkowski, A., et al. (2004). Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4, 1307-1318. doi: 10.1016/j.intimp.2004.05.006
66. Landowski, L. M., Pavez, M., Brown, L. S., Gasperini, R., Taylor, B. V., West, A. K., et al. (2016). Low-density lipoprotein receptor-related proteins in a novel mechanism of axon guidance and peripheral nerve regeneration. J. Biol. Chem. 291, 1092-1102. doi: 10.1074/jbc.M115.668996
67. Lees, A. J., Hardy, J., and Revesz, T. (2009). Parkinson's disease. Lancet 373, 2055-2066. doi: 10.1016/S0140-6736(09)60492-X
68. Lewis, K. E., Chung, R. S., West, A. K., and Chuah, M. I. (2012). Distribution of exogenous metallothionein following intraperitoneal and intramuscular injection of metallothionein-deficient mice. Histol. Histopathol. 27, 1459-1470. doi: 10.14670/HH-27.1459
69. Luk, K. C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J. Q., et al. (2012). Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338, 949-953. doi: 10.1126/science.1227157
70. Lutsenko, S., Barnes, N. L., Bartee, M. Y., and Dmitriev, O. Y. (2007). Function and regulation of human copper-transporting ATPases. Physiol. Rev. 87, 1011-1046. doi: 10.1152/physrev.00004.2006
71. Magaki, S., Raghavan, R., Mueller, C., Oberg, K. C., Vinters, H. V., and Kirsch, W. M. (2007). Iron, copper, and iron regulatory protein 2 in Alzheimer's disease and related dementias. Neurosci. Lett. 418, 72-76. doi: 10.1016/j.neulet.2007.02.077
72. Manso, Y., Adlard, P. A., Carrasco, J., Vašák, M., and Hidalgo, J. (2011). Metallothionein and brain inflammation. JBIC J. Biol. Inorg. Chem. 16, 1103. doi: 10.1007/s00775-011-0802-y
73. Manso, Y., Carrasco, J., Comes, G., Meloni, G., Adlard, P. A., Bush, A. I., et al. (2012a). Characterization of the role of metallothionein-3 in an animal model of Alzheimer's disease. Cell. Mol. Life Sci. 69, 3683-3700. doi: 10.1007/s00018-012-1047-9
74. Manso, Y., Carrasco, J., Comes, G., Adlard, P. A., Bush, A. I., and Hidalgo, J. (2012b). Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimer's disease. Cell. Mol. Life Sci. 69, 3665-3681. doi: 10.1007/s00018-012-1045-y
75. Manso, Y., Comes, G., López-Ramos, J. C., Belfiore, M., Molinero, A., Giralt, M., et al. (2016). Overexpression of metallothionein-1 modulates the phenotype of the Tg2576 mouse model of Alzheimer's disease. J. Alzheimers Dis. 51, 81-95. doi: 10.3233/JAD-151025
76. Margoshes, M., and Vallee, B. L. (1957). A cadmium protein from equine kidney cortex. J. Am. Chem. Soc. 79, 4813-4814. doi: 10.1021/ja01574a064
77. Marques, O., and Outeiro, T. F. (2012). Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis. 3, e350. doi: 10.1038/cddis.2012.94
78. Mayo, K. E., and Palmiter, R. D. (1981). Glucocorticoid regulation of metallothionein-I mRNA synthesis in cultured mouse cells. J. Biol. Chem. 256, 2621-2624
79. McCarty, M. F. (2006). Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med. Hypotheses 67, 251-269. doi: 10.1016/j.mehy.2006.01.013
80. Meloni, G., and Vašák, M. (2011). Redox activity of a-synuclein-Cu is silenced by Zn 7-metallothionein-3. Free Radic. Biol. Med. 50, 1471-1479. doi: 10.1016/j.freeradbiomed.2011.02.003
81. Meloni, G., Sonois, V., Delaine, T., Guilloreau, L., Gillet, A., Teissié, J., et al. (2008). Metal swap between Zn7-metallothionein-3 and amyloid-ß-Cu protects against amyloid-ß toxicity. Nat. Chem. Biol. 4, 366-372. doi: 10.1038/nchembio.89
82. Méndez-Armenta, M., Villeda-Hernández, J., Barroso-Moguel, R., Nava-Ruíz, C., Jiménez-Capdeville, M. E., and Ríos, C. (2003). Brain regional lipid peroxidation and metallothionein levels of developing rats exposed to cadmium and dexamethasone. Toxicol. Lett. 144, 151-157. doi: 10.1016/S0378-4274(03)00199-1
83. Michael, G. J., Esmailzadeh, S., Moran, L. B., Christian, L., Pearce, R. K., and Graeber, M. B. (2011). Up-regulation of metallothionein gene expression in parkinsonian astrocytes. Neurogenetics 12, 295-305. doi: 10.1007/s10048-011-0294-5
84. Miotto, M. C., Rodriguez, E. E., Valiente-Gabioud, A. A., Torres-Monserrat, V., Binolfi, A., Quintanar, L., et al. (2014). Site-specific copper-catalyzed oxidation of a-synuclein: tightening the link between metal binding and protein oxidative damage in Parkinson's disease. Inorg. Chem. 53, 4350-4358. doi: 10.1021/ic4031377
85. Montes, S., Rivera-Mancia, S., Diaz-Ruiz, A., Tristan-Lopez, L., and Rios, C. (2014). Copper and copper proteins in Parkinson's disease. Oxid. Med. Cell. Longev. 2014:147251. doi: 10.1155/2014/147251
86. Noe, E., Marder, K., Bell, K. L., Jacobs, D. M., Manly, J. J., and Stern, Y. (2004). Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Mov. Disord. 19, 60-67. doi: 10.1002/mds.10633
87. Nordberg, M. (1998). Metallothioneins: historical review and state of knowledge. Talanta 46, 243-254. doi: 10.1016/s0039-9140(97)00345-7
88. Nussbaum, R. L. (2017). Genetics of synucleinopathies. Cold Spring Harb. Perspect. Med. doi: 10.1101/cshperspect.a024109. [Epub ahead of print]
89. Otsuka, F. (2004). Transcriptional regulation of the metallothionein genes. J. Health Sci. 50, 332-335. doi: 10.1248/jhs.50.332
90. Paik, S. R., Shin, H. J., Lee, J. H., Chang, C. S., and Kim, J. (1999). Copper (II)-induced self-oligomerization of a-synuclein. Biochem. J. 340, 821-828. doi: 10.1042/bj3400821
91. Pall, H. S., Blake, D. R., Gutteridge, J. M., Williams, A. C., Lunec, J., Hall, M., et al. (1987). Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 330, 238-241. doi: 10.1016/S0140-6736(87)90827-0
92. Palmiter, R. D., Findley, S. D., Whitmore, T. E., and Durnam, D. M. (1992). MT-III, a brain-specific member of the metallothionein gene family. Proc. Natl. Acad. Sci. U.S.A. 89, 6333-6337. doi: 10.1073/pnas.89.14.6333
93. Pedersen, M. Ø., Larsen, A., Stoltenberg, M., and Penkowa, M. (2009). Cell death in the injured brain: roles of metallothioneins. Prog. Histochem. Cytochem. 44, 1-27. doi: 10.1016/j.proghi.2008.10.002
94. Petro, A., Sexton, H. G., Miranda, C., Rastogi, A., Freedman, J. H., and Levin, E. D. (2016). Persisting neurobehavioral effects of developmental copper exposure in wildtype and metallothionein 1 and 2 knockout mice. BMC Pharmacol. Toxicol. 17:55. doi: 10.1186/s40360-016-0096-3
95. Pinto, M., Nissanka, N., Peralta, S., Brambilla, R., Diaz, F., and Moraes, C. T. (2016). Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation. Mol. Neurodegener. 11:25. doi: 10.1186/s13024-016-0090-7
96. Pountney, D. L., Dickson, T. C., Power, J. H. T., Vickers, J. C., West, A. J., and Gai, W. P. (2011). Association of metallothionein-III with oligodendroglial cytoplasmic inclusions in multiple system atrophy. Neurotox. Res. 19, 115-122. doi: 10.1007/s12640-009-9146-6
97. Pountney, D. L., Kägi, J. H. R., and Vašák, M. (1995). "Metallothioneins," in Handbook on Metal-Ligand Interaction in Biological Fluids, Vol. 1, ed G. Berthon (New York, NY: Marcel Dekker), 431-442
98. Proukakis, C., Dudzik, C. G., Brier, T., MacKay, D. S., Cooper, J. M., Millhauser, G. L., et al. (2013). A novel a-synuclein missense mutation in Parkinson disease. Neurology 80, 1062-1064. doi: 10.1212/WNL.0b013e31828727ba
99. Pushkar, Y., Robison, G., Sullivan, B., Fu, S. X., Kohne, M., Jiang, W., et al. (2013). Aging results in copper accumulations in glial fibrillary acidic protein-positive cells in the subventricular zone. Aging Cell 12, 823-832. doi: 10.1111/acel.12112
100. Quaife, C., Hammer, R. E., Mottet, N. K., and Palmiter, R. D. (1986). Glucocorticoid regulation of metallothionein during murine development. Dev. Biol. 118, 549-555. doi: 10.1016/0012-1606(86)90025-4
101. Radford, R., Wong, M. B., and Pountney, D. L. (2014). "Neurodegenerative aspects of multiple system atrophy," in Handbook of Neurotoxicity, Vol. 110, ed R. M. Kostrzewa (New York, NY: Springer Science+Business Media), 2157-2180
102. Rcom-H'cheo-Gauthier, A. N., Osborne, S. L., Meedeniya, A. C. B., and Pountney, D. L. (2016). Calcium: Alpha-synuclein interactions in Alpha-Synucleinopathies. Front. Neurosci. 10:570. doi: 10.3389/fnins.2016.00570
103. Richards, R. I., Heguy, A., and Karin, M. (1984). Structural and functional analysis of the human metallothionein-IA gene: differential induction by metal ions and glucocorticoids. Cell 37, 263-272. doi: 10.1016/0092-8674(84)90322-2
104. Rofe, A. M., Philcox, J. C., Haynes, D. R., Whitehouse, M. W., and Coyle, P. (1992). Changes in plasma zinc, copper, iron, and hepatic metallothionein in adjuvant-induced arthritis treated with cyclosporin. Biol. Trace Elem. Res. 34, 237-248. doi: 10.1007/BF02783679
105. Rose, F., Hodak, M., and Bernholc, J. (2011). Mechanism of copper(II)-induced misfolding of Parkinson's disease protein. Sci. Rep. 1:11. doi: 10.1038/srep00011
106. Sadhu, C., and Gedamu, L. (1989). Metal-specific posttranscriptional control of human metallothionein genes. Mol. Cell. Biol. 9, 5738-5741. doi: 10.1128/MCB.9.12.5738
107. Sas, K., Robotka, H., Toldi, J., and Vécsei, L. (2007). Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J. Neurol. Sci. 257, 221-239. doi: 10.1016/j.jns.2007.01.033
108. Sawada, H., Kohno, R., Kihara, T., Izumi, Y., Sakka, N., Ibi, M., et al. (2004). Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes a-synuclein inclusions. J. Biol. Chem. 279, 10710-10719. doi: 10.1074/jbc.M308434200
109. Sharma, S., and Ebadi, M. (2014a). Significance of metallothioneins in aging brain. Neurochem. Int. 65, 40-48. doi: 10.1016/j.neuint.2013.12.009
110. Sharma, S., and Ebadi, M. (2014b). The Charnoly body as a universal biomarker of cell injury. Biomarkers Genomic Med. 6, 89-98. doi: 10.1016/j.bgm.2014.03.004
111. Sharma, S., Moon, C. S., Khogali, A., Haidous, A., Chabenne, A., Ojo, C., et al. (2013a). Biomarkers in Parkinson's disease (recent update). Neurochem. Int. 63, 201-229. doi: 10.1016/j.neuint.2013.06.005
112. Sharma, S., Rais, A., Sandhu, R., Nel, W., and Ebadi, P. M. (2013b). Clinical significance of metallothioneins in cell therapy and nanomedicine. Int. J. Nanomed. 8, 1477-1488. doi: 10.2147/IJN.S42019
113. Shastri, A., Bonifati, D. M., and Kishore, U. (2013). Innate immunity and neuroinflammation. Mediators Inflamm. 2013:342931. doi: 10.1155/2013/342931
114. Shin, J. H., Dawson, V. L., and Dawson, T. M. (2009). Snapshot: pathogenesis of Parkinson's Disease. Cell 139, 440.e1-440.e2. doi: 10.1016/j.cell.2009.09.026
115. Shiraga, H., Pfeiffer, R. F., and Ebadi, M. (1993). The effects of 6-hydroxydopamine and oxidative stress on the level of brain metallothionein. Neurochem. Int. 23, 561-566. doi: 10.1016/0197-0186(93)90104-D
116. Siddiqui, A., Rane, A., Rajagopalan, S., Chinta, S. J., and Andersen, J. K. (2016). Detrimental effects of oxidative losses in parkin activity in a model of sporadic Parkinson's disease are attenuated by restoration of PGC1alpha. Neurobiol. Dis. 93, 115-120. doi: 10.1016/j.nbd.2016.05.009
117. Sidhu, A., Wersinger, C., and Vernier, P. (2004). Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse? FASEB J. 18, 637-647. doi: 10.1096/fj.03-1112rev
118. Spillantini, M. G., and Goedert, M. (2000). The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 920, 16-27. doi: 10.1111/j.1749-6632.2000.tb06900.x
119. Squitti, R., Siotto, M., Arciello, M., and Rossi, L. (2016). Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease. Metallomics 8, 863-873. doi: 10.1039/c6mt00101g
120. Stefanis, L. L. (2012). a-Synuclein in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2:9399. doi: 10.1101/cshperspect.a009399
121. Thanvi, B. R., and Lo, T. C. (2004). Long term motor complications of levodpa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 80, 452-458. doi: 10.1136/pgmj.2003.013912
122. Tokuda, E., Watanabe, S., Okawa, E., and Ono, S. I. (2015). Regulation of intracellular copper by induction of endogenous metallothioneins improves the disease course in a mouse model of amyotrophic lateral sclerosis. Neurotherapeutics 12, 461-476. doi: 10.1007/s13311-015-0346-x
123. Uchida, Y. (2010). Molecular mechanisms of regeneration in Alzheimer's disease brain. Geriatr. Gerontol. Int. 10(Suppl. 1), S158-S168. doi: 10.1111/j.1447-0594.2010.00607.x
124. Valdinocci, D., Radford, R. A., Siow, S. M., Chung, R. S., and Pountney, D. L. (2017). Potential modes of intercellular a-Synuclein transmission. Int. J. Mol. Sci. 18:e469. doi: 10.3390/ijms18020469
125. Valensin, D., Dell'Acqua, S., Kozlowski, H., and Casella, L. (2016). Coordination and redox properties of copper interaction with a-synuclein. J. Inorg. Biochem. 163, 292-300. doi: 10.1016/j.jinorgbio.2016.04.012
126. Van der Perren, A., Van den Haute, C., and Baekelandt, V. (2015). Viral vector-based models of Parkinson's disease. Curr. Top. Behav. Neurosci. 22, 271-301. doi: 10.1007/7854_2014_310
127. Vasudevaraju, P., Jyothsna, T., Shamasundar, N. M., Rao, S. K., Balaraj, B. M., Rao, K. S. J., et al. (2010). New evidence on iron, copper accumulation and zinc depletion and its correlation with DNA integrity in aging human brain regions. Indian J. Psychiatry 52, 140. doi: 10.4103/0019-5545.64590
128. Vekrellis, K., Rideout, H. J., and Stefanis, L. (2004). Neurobiology of a-synuclein. Mol. Neurobiol. 30, 1-21. doi: 10.1385/MN:30:1:001
129. Villar-Piqué, A., da Fonseca, T. L., Sant'Anna, R., Szegö, é. M., Fonseca-Ornelas, L., Pinho, R., et al. (2016). Environmental and genetic factors support the dissociation between a-synuclein aggregation and toxicity. Proc. Natl. Acad. Sci. U.S.A. 113, E6506-E6515. doi: 10.1073/pnas.1606791113
130. Vieira, B. D., Radford, R. A., Chung, R. S., Guillemin, G. J., and Pountney, D. L. (2015). Neuroinflammation in multiple system atrophy: response to and cause of a-synuclein aggregation. Front. Cell. Neurosci. 9:437. doi: 10.3389/fncel.2015.00437
131. Waldron, K. J., Rutherford, J. C., Ford, D., and Robinson, N. J. (2009). Metalloproteins and metal sensing. Nature 460, 823-830. doi: 10.1038/nature08300
132. Wan, O. W., and Chung, K. K. (2012). The role of alpha-synuclein oligomerization and aggregation in cellular and animal models of Parkinson's disease. PLoS ONE 7:e38545. doi: 10.1371/journal.pone.0038545
133. West, A. K., Hidalgo, J., Eddins, D., Levin, E. D., and Aschner, M. (2008). Metallothionein in the central nervous system: roles in protection, regeneration and cognition. Neurotoxicology 29, 489-503. doi: 10.1016/j.neuro.2007.12.006
134. West, A. K., Stallings, R., Hildebrand, C. E., Chiu, R., Karin, M., and Richards, R. I. (1990). Human metallothionein genes: structure of the functional locus at 16q13. Genomics 8, 513-518. doi: 10.1016/0888-7543(90)90038-v
135. Wirdefeldt, K., Adami, H., Cole, P., Trichopoulos, D., and Mandel, J. (2011). Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 26:1. doi: 10.1007/s10654-011-9581-6
136. Wong, Y. C., and Krainc, D. (2017). a-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat. Med. 23, 1-13. doi: 10.1038/nm.4269
137. Yates, D. (2011). Neurodegenerative disease: a-synuclein gets a new look. Nat. Rev. Neurosci. 12, 550. doi: 10.1038/nrn3106
138. Yavich, L., Tanila, H., Vepsäläinen, S., and Jäkälä, P. (2004). Role of a-synuclein in presynaptic dopamine recruitment. J. Neurosci. 24, 11165-11170. doi: 10.1523/JNEUROSCI.2559-04.2004
139. Zatta, P., Drago, D., Zambenedetti, P., Bolognin, S., Nogara, E., Peruffo, A., et al. (2008). Accumulation of copper and other metal ions, and metallothionein I/II expression in the bovine brain as a function of aging. J. Chem. Neuroanat. 36, 1-5. doi: 10.1016/j.jchemneu.2008.02.008